Page last updated: 2024-10-30

lomustine and Metastase

lomustine has been researched along with Metastase in 85 studies

Research Excerpts

ExcerptRelevanceReference
"This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma."9.11Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. ( Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005)
"A Phase II trial comprising patients with metastatic uveal melanoma (Stage IVB) was undertaken to determine the activity of bleomycin, vincristine, lomustine, and dacarbazine (BOLD) chemotherapy with human leukocyte interferon, as well as the progression-free and overall survival of the patients according to the substage before treatment."9.10Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. ( Eskelin, S; Hahka-Kemppinen, M; Kivelä, T; Muhonen, T; Nikkanen, V; Pyrhönen, S; Summanen, P; Tarkkanen, A, 2002)
"40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)."9.07Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994)
"Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)."9.05Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985)
"Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1."7.67Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984)
"Forty-six consecutive, evaluable patients with a diagnosis of metastatic melanoma without prior chemotherapy were treated with bleomycin, vincristine, lomustine, and DTIC (BOLD)."7.67Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. ( Foltz, AT; York, RM, 1988)
"Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5."7.67The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. ( English, JS; Lever, RS; MacKie, RM; Young, DW, 1985)
"Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine."7.67Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985)
"Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%."7.66Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980)
"This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b."6.71Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. ( Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS, 2003)
"This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma."5.11Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. ( Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005)
"A Phase II trial comprising patients with metastatic uveal melanoma (Stage IVB) was undertaken to determine the activity of bleomycin, vincristine, lomustine, and dacarbazine (BOLD) chemotherapy with human leukocyte interferon, as well as the progression-free and overall survival of the patients according to the substage before treatment."5.10Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. ( Eskelin, S; Hahka-Kemppinen, M; Kivelä, T; Muhonen, T; Nikkanen, V; Pyrhönen, S; Summanen, P; Tarkkanen, A, 2002)
"40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)."5.07Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994)
"Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)."5.05Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985)
"Forty-three patients with inoperable and/or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl) -3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m2 for two days)."5.04[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial]. ( Buge, A; Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, HT, 1976)
"Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days)."5.04Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial. ( Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P, 1977)
"As reported earlier, a chemotherapy regimen that consisted of dacarbazine, vincristine, lomustine, and bleomycin (DOBC) combined with natural leukocyte interferon (IFN) has been administered with favorable results to patients with metastatic melanoma."3.69The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. ( Hahka-Kemppinen, M; Hernberg, M; Muhonen, T; Pyrhönen, S; Turunen, JP, 1996)
"In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination."3.68Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. ( Bliss, JM; Gore, ME; Lakhani, S; McElwain, TJ; Perren, TJ; Selby, P, 1990)
"Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1."3.67Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984)
"Forty-six consecutive, evaluable patients with a diagnosis of metastatic melanoma without prior chemotherapy were treated with bleomycin, vincristine, lomustine, and DTIC (BOLD)."3.67Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. ( Foltz, AT; York, RM, 1988)
"Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5."3.67The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. ( English, JS; Lever, RS; MacKie, RM; Young, DW, 1985)
"Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine."3.67Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985)
"Sixty patients with renal adenocarcinoma have been treated with five different immunotherapy trials consisting of 1) Transfer Factor (TF), 2) TF and Bacillus Calmette-Guerin (BCG), 3) TF, BCG, Chloroethyl-cyclohexy-nitrosurea (CCNU) and megestrol acetate (Megase), 4) BCG, CCNU, and Megase, or 5) BCG."3.66A critical review of immunotherapy of disseminated renal adenocarcinoma. ( Bukowski, RM; James, RE; Montie, JE; Stewart, BH; Straffon, RA, 1982)
"Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%."3.66Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980)
"Forty-three patients with inoperable or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of Adriamycin (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (60 mg/m2 for 2 days)."3.65Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail. ( Gauthier, H; Huguenin, P; Lheritier, J; Mathe, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, TH, 1976)
"A median of two cycles were given until disease progression or grade 3/4 toxicity."2.71Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. ( Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP, 2003)
"This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b."2.71Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. ( Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS, 2003)
"The distant metastasis rate was significantly lower in group B (P less than ."2.67Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. ( Arriagada, R; Douillard, JY; Lacombe-Terrier, MJ; Laplanche, A; Le Chevalier, T; Martin, M; Quoix, E; Ruffie, P; Tarayre, M, 1991)
"Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds."2.64Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978)
"Brain metastasis occurred in 0/14 patients in the PCI and 4/15 in the non-PCI (P less than or equal to ."2.64Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. ( Cooper, MR; Ferree, C; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; White, DR, 1977)
"Pituitary tumors are mostly benign lesions, although 5-35% are locally invasive."1.30The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. ( Besser, GM; Grossman, AB; Kaltsas, GA; Monson, JP; Mukherjee, JJ; Plowman, PN, 1998)
"Six of them had tumor metastasis with in 6 months after the initial treatment(s)."1.27[Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma]. ( Matsumoto, S; Oi, S; Raimondi, AJ, 1985)
" The therapy is to be used effectfully only then, when indication, dosage and control of the patients are performed critically and exactly."1.26[Chemotherapy of malignant solid tumors]. ( Knöll, P; Siering, H, 1980)
"One patient with gastric cancer attained a partial remission with a duration of remission of 9."1.26[Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract]. ( Hartmann, D; Obrecht, JP; Stalder, GA, 1978)
"Three patients developed CNS metastasis while on treatment."1.26Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Hortobagyi, GN; Tashima, CK; Waterfield, WC, 1978)
" Data from other centers have shown that augmentation of remissions for melanoma patients occurred when BCG was combined with DTIC, vincristine, and allogeneic tumor cells."1.26Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. ( Burgess, MA; Gottlieb, J; Gutterman, JU; Hersh, EM; Mavligit, GM; Reed, R, 1976)
"Untreated meningeal carcinomatosis is a uniformly fatal type of metastatic disease presenting with many protean signs and symptoms."1.26Meningeal carcinomatosis. Case report and review of the literature. ( Bender, J; Bramlet, D; Giliberti, J, 1976)
"Distant metastases were more frequent in the R series, being reported in 99 (82%) compared with 82 (71%) of the RC patients (P less than 0."1.26Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung: the results at 36 months. 2nd report to the Medical Research Council on the 2nd small-cell study. ( , 1981)
"Hypercalcemia is very uncommon in small cell (oat cell) carcinoma of the lung."1.25Hypercalcemia in small cell (oat cell) carcinoma of the lung. Coincident parathyroid adenoma in one case. ( Bowman, DM; Dubé, WJ; Levitt, M, 1975)
"The growth rate of spherical pulmonary metastases was studied in 15 patients with osseous and soft tissue sarcoma."1.25Growth rate of pulmonary metastases in human sarcomas. ( Band, PR; Kocandrle, C, 1975)

Research

Studies (85)

TimeframeStudies, this research(%)All Research%
pre-199067 (78.82)18.7374
1990's10 (11.76)18.2507
2000's6 (7.06)29.6817
2010's2 (2.35)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Taylor, RE1
Howman, AJ1
Wheatley, K1
Brogden, EE1
Large, B1
Gibson, MJ1
Robson, K1
Mitra, D1
Saran, F1
Michalski, A1
Pizer, BL1
Buzás, K1
Marton, A1
Vizler, C1
Gyukity-Sebestyén, E1
Harmati, M1
Nagy, K1
Zvara, Á1
Katona, RL1
Tubak, V1
Endrész, V1
Németh, IB1
Oláh, J1
Vígh, L1
Bíró, T1
Kemény, L1
Fewer, D1
Wilson, CB2
Boldrey, EB2
Enot, JK1
Skorupski, KA1
Rodriguez, CO1
Krick, EL1
Clifford, CA1
Ward, R1
Kent, MS1
Pyrhönen, S6
Hahka-Kemppinen, M5
Muhonen, T4
Nikkanen, V1
Eskelin, S1
Summanen, P1
Tarkkanen, A1
Kivelä, T2
Nystrom, ML1
Steele, JP1
Shamash, J1
Neville, F1
Oliver, RT1
Suciu, S1
Hansson, J1
Kruit, WH1
Vuoristo, MS3
Kloke, O1
Gore, M1
Parvinen, LM2
Kumpulainen, E3
Humblet, Y1
Lens, MB1
Eisen, TG1
Seppä, H1
Korpela, M3
Kellokumpu-Lehtinen, P2
Siering, H1
Knöll, P1
Kelsen, D1
Osterlind, K2
Sörenson, S1
Hansen, HH2
Dombernowsky, P1
Hirsch, FR1
Hansen, M2
Rørth, M1
Bernengo, MG1
Lisa, F1
Meregalli, M1
Doveil, GC1
Ojala, A1
Nikkanen, VN1
Paloheimo, S1
Palojoki, A1
Thölix, E1
Xavier, AM1
Kasimis, BS1
Wu, SY1
Kaneshiro, CA1
Chahinian, AP1
Green, G1
Holland, JF2
Carmo-Pereira, J1
Costa, FO1
Henriques, E1
Montie, JE1
Bukowski, RM1
James, RE1
Straffon, RA1
Stewart, BH1
Green, MR1
Dillman, RO1
Horton, C1
Tirelli, U1
Frustaci, S1
Galligioni, E1
Veronesi, A1
Trovò, MG1
Magri, DM1
Crivellari, D1
Roncadin, M1
Tumolo, S1
Grigoletto, E1
Vuoristo, M1
Gröhn, P2
Turunen, M1
Joensuu, H1
Tiusanen, K1
Nevantaus, A1
Samuel, LM1
Harvey, VJ1
Mitchell, PL1
Thompson, PI1
Mak, D1
Melville, P1
Evans, BD1
Hernberg, M2
Turunen, JP2
Kangas, L1
Kaltsas, GA1
Mukherjee, JJ1
Plowman, PN1
Monson, JP1
Grossman, AB1
Besser, GM1
Brunner, KW1
Sonntag, RW1
Cannon, PJ1
Wajsman, Z1
Baumgartner, G1
Merrin, C1
Folke, E1
Per, J1
Britta, W1
De Wasch, G1
Bernheim, J1
Michel, J2
Lejeune, F1
Kenis, Y2
Hahn, DM1
Schimpff, SC1
Ruckdeschel, JC1
Wiernik, PH1
Richards, F2
Muss, HB2
White, DR2
Cooper, MR2
Spurr, CL2
Band, PR2
Canellos, GP1
Sears, M1
Israel, L1
Pocock, SJ1
Everall, JD1
Dowd, PM1
Moertel, CG1
Engstrom, P1
Lavin, PT1
Gelber, RD1
Carbone, PP1
Bowman, DM1
Dubé, WJ1
Levitt, M1
Williams, CJ1
Vosika, GJ2
Panettiere, FJ1
Mulder, JH1
Smink, T1
Van Putten, LM1
Valdivieso, M2
Bedikian, A1
Burgess, MA4
Rodriguez, V1
Hersh, EM2
Bodey, GP2
Mavligit, GM2
Pouillart, P3
Mathé, G3
Palangie, T1
Lheritier, J3
Poisson, M3
Huguenin, P3
Gautier, H2
Morin, P3
Parrot, R3
Paoletti, P1
Robustelli della Cuna, G1
Knerich, R1
Strada, MR1
Bedikian, AY1
Staab, R1
Livingston, R1
Hartmann, D1
Obrecht, JP1
Stalder, GA1
Ryan, MJ1
Fortuny, IA1
Meyer, C1
Kiang, DT1
Theologides, A1
Kennedy, BJ1
Hasegawa, H1
Shapiro, WR1
Posner, JB1
Jackson, DV1
Ferree, C1
Waterfield, WC1
Tashima, CK1
Hortobagyi, GN1
Blumenschein, GR1
Buzdar, AU1
Comis, RL1
Gutterman, JU1
Reed, R1
Gottlieb, J1
Cedermark, BJ1
Didolkar, MS1
Elias, EG1
Buge, A1
Thy, HT1
Levin, VA1
Wilson, WL1
Andrews, NC1
Frelick, RW1
Nealon, TF1
Bick, RL1
Adams, T1
Aranha, GV1
Grage, TB1
Tejada, F1
Eisenberger, MA1
Broder, LA1
Cohen, MH1
Simon, R1
Palshof, T1
Mouridsen, H1
Bramlet, D1
Giliberti, J1
Bender, J1
Mannes, P1
Derriks, R1
Moens, R1
Laurent, C1
Thy, TH1
Gauthier, H1
Kocandrle, C1
Gutin, PH1
Kumar, AR1
Levin, V1
Powell, M1
Enot, KJ1
Garrett, MJ1
Hughes, HJ1
Ryall, RD1
Hildebrand, J1
Brihaye, J1
Wagenknecht, L1
Carter, SK1
Engstrom, PF1
Catalano, RB1
Creech, RH1
Baumöhl, J1
Jurga, L1
Klimo, J1
Jutka, K1
Zábranská, M1
Lakhani, S1
Selby, P1
Bliss, JM1
Perren, TJ1
Gore, ME1
McElwain, TJ1
Le Chevalier, T1
Arriagada, R1
Quoix, E1
Ruffie, P1
Martin, M1
Tarayre, M1
Lacombe-Terrier, MJ1
Douillard, JY1
Laplanche, A1
Cohen, SM1
Ohnuma, T1
Ambinder, EP1
York, RM1
Foltz, AT1
Kühböck, J1
Pötzi, P1
Madaras, T1
Young, DW1
Lever, RS1
English, JS1
MacKie, RM1
Marangolo, M1
Pezzuoli, G1
Marubini, E1
Amadori, D1
Boracchi, P1
Cocconi, G1
Cunsolo, A1
Garcea, D1
Germiniani, R1
Luporini, G1
Shelley, W1
Quirt, I1
Bodurtha, A1
Iscoe, N1
Russell, J1
Paterson, A1
Young, V1
Jacobs, RH1
Greenburg, A1
Bitran, JD1
Hoffman, PC1
Albain, KS1
Desser, R1
Potkul, L1
Golomb, HM1
Chasen, MR1
Falkson, G1
van der Merwe, CA1
Dreyer, RJ1
Terblanche, AP1
Eagan, RT1
Frytak, S1
Richardson, RL1
Creagan, ET1
Nichols, WC1
Mohiuddin, M1
Cantor, RJ1
Biermann, W1
Weiss, SM1
Barbot, D1
Rosato, FE1
Page, JP1
Levi, JA1
Woods, RL1
Tattersall, MN1
Fox, RM1
Coates, AS1
Bajetta, E1
Buzzoni, R1
Viviani, S1
Vaglini, M1
Nava, M1
Bonadonna, G1
Oi, S1
Matsumoto, S1
Raimondi, AJ1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606]Phase 158 participants (Actual)Interventional1999-04-30Completed
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348]Early Phase 15 participants (Actual)Interventional2011-11-01Terminated (stopped due to Slow, insufficient accrual.)
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250]Phase 2264 participants (Actual)Interventional2019-11-28Active, not recruiting
Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy[NCT04654234]20 participants (Anticipated)Observational [Patient Registry]2020-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Serious and Non-Serious Adverse Events

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.

InterventionParticipants (Count of Participants)
1/Intravenous (IV) Tetrahydrouridine (THU)2

Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0

[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions

Interventionadverse events (Number)
Day 1 Adverse EventsDay 2, Grade 2 HypoalbuminemiaDay 2, Grade 3 AnemiaDay 3 Adverse EventsDay 4 Adverse EventsDay 5 Adverse Events
1/Intravenous (IV) Tetrahydrouridine (THU)011000

Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans

Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year

InterventionmSv/MBq (Mean)
AdrenalsBrainBreastsGallbladder wallLower large intestine wallSmall intestineStomach wallUpper large intestine wallHeart wallKidneysLiverLungsMuscleOvariesPancreasRed marrowOsteogenic cellsSkinSpleenTestesThymusThyroidUrinary bladder wallUterus
1/Intravenous (IV) Tetrahydrouridine (THU)1.838.171.034.052.522.131.902.041.105.266.021.821.161.571.631.141.718.651.691.031.128.237.961.63

Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection

Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection

InterventionTBR ratio (Number)
Pt 1 L. Parotid adenosquam. cell ca at 9 minPt 1 L. Parotid adenosquam. cell ca at 32 minPt 1 L. Parotid adenosquam. cell ca at 56 minPt 1 L. Parotid adenosquam. cell ca at 2 hrsPt 2 R. Parapharyngeal Spindle Cell Ca at 9 minPt 2 R. Parapharyngeal Spindle Cell Ca at 32 minPt 2 R. Parapharyngeal Spindle Cell Ca at 56 minPt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrsPt 3 Non-small Cell Lung Ca at 9 minPt 3 Non-small Cell Lung Ca at 32 minPt 3 Non-small Cell Lung Ca at 56 minPt 3 Non-small Cell Lung Ca at 2 hrsPt 4 Non-small Cell Lung Ca at 9 minPt 4 Non-small Cell Lung Ca at 32 minPt 4 Non-small Cell Lung Ca at 56 minPt 4 Non-small Cell Lung Ca at 2 hrsPt 5 Hepatocellular Ca at 9 minPt 5 Hepatocellular Ca at 32 minPt 5 Hepatocellular Ca at 56 minPt 5 Hepatocellular Ca at 2 hrs
1/Intravenous (IV) Tetrahydrouridine (THU)1.41.51.51.61.91.71.71.61.41.41.51.72.42.11.62.0NANANANA

Reviews

5 reviews available for lomustine and Metastase

ArticleYear
Systemic chemotherapy in the treatment of malignant melanoma.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as

2003
Chemotherapy of esophageal cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub

1984
The current management of malignancy. IV.-Cancer of the lung.
    Alaska medicine, 1975, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adrenocorticotropic Hormone; Adult; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, S

1975
DTIC (NSC-45388) in malignant melanoma: a perspective.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation;

1976
A pharmacologic basis for brain tumor chemotherapy.
    Seminars in oncology, 1975, Volume: 2, Issue:1

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Doxorubicin; Drug Interactions; Huma

1975

Trials

34 trials available for lomustine and Metastase

ArticleYear
Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 111, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemoradiotherapy;

2014
Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Lomustine; Neoplas

1972
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Cancer, 2002, Dec-01, Volume: 95, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2002
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
    Melanoma research, 2003, Volume: 13, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylatin

2003
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Su

2003
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Melanoma research, 2005, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo

2005
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung.
    Cancer research, 1983, Volume: 43, Issue:12 Pt 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyc

1983
Combination chemotherapy in metastatic or recurrent non-small cell bronchogenic carcinoma. 5-year results.
    Strahlentherapie, 1983, Volume: 159, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Clinical Trial

1983
Combination chemotherapy with 5-fluorouracil, CCNU, and vincristine in metastatic colorectal carcinoma.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl

1984
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1984
Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans;

1994
Intermittent interferon and polychemotherapy in metastatic melanoma.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administra

1995
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano

1994
Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 1997, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; CD4-CD8 Ratio; Combi

1997
Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Drug Evaluation; Female; Humans; Kidney Neoplasms;

1977
CCNU, bleomycin, and methylprednisolone with or without adriamycin in renal cel carcinoma: a randomized trial.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Therapy, Combination; Female; Hu

1977
Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast.
    Cancer treatment reports, 1977, Volume: 61, Issue:7

    Topics: Adult; Aged; Bleomycin; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation;

1977
Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
    Cancer treatment reports, 1979, Volume: 63, Issue:1

    Topics: Adult; Aged; Bleomycin; Clinical Trials as Topic; Dacarbazine; Drug Resistance; Drug Therapy, Combin

1979
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
    Surgery, 1979, Volume: 85, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N

1979
Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1977, Issue:62

    Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy,

1977
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
    Acta neurochirurgica, 1978, Volume: 41, Issue:4

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu

1978
Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil.
    Cancer treatment reports, 1978, Volume: 62, Issue:10

    Topics: Administration, Oral; Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Eva

1978
CCNU, vinblastine, and delalutin therapy in renal cell carcinoma.
    Medical and pediatric oncology, 1978, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Hydrox

1978
Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study.
    JAMA, 1977, Jun-20, Volume: 237, Issue:25

    Topics: Adult; Aged; Brain; Brain Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Therapy, Combina

1977
DTIC (NSC-45388) in malignant melanoma: a perspective.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation;

1976
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms;

1976
[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
    La Nouvelle presse medicale, 1976, Jun-19, Volume: 5, Issue:25

    Topics: Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy,

1976
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adult; Aged; Altretamine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Eval

1976
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea

1977
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
    Journal of the National Cancer Institute, 1991, Mar-20, Volume: 83, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined

1991
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
    Journal of the National Cancer Institute, 1991, Mar-20, Volume: 83, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined

1991
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
    Journal of the National Cancer Institute, 1991, Mar-20, Volume: 83, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined

1991
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
    Journal of the National Cancer Institute, 1991, Mar-20, Volume: 83, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined

1991
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
    Tumori, 1989, Jun-30, Volume: 75, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C

1989
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 1988, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To

1988
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do

1985
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
    American journal of clinical oncology, 1985, Volume: 8, Issue:5

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic

1985

Other Studies

47 other studies available for lomustine and Metastase

ArticleYear
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
    The Journal of investigative dermatology, 2016, Volume: 136, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamy

2016
Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
    Veterinary and comparative oncology, 2009, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Dog D

2009
[Chemotherapy of malignant solid tumors].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1980, Jul-01, Volume: 35, Issue:13

    Topics: Bleomycin; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Kidney Neo

1980
Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung: the results at 36 months. 2nd report to the Medical Research Council on the 2nd small-cell study.
    British journal of cancer, 1981, Volume: 44, Issue:5

    Topics: Aged; Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lomustine;

1981
Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.
    International journal of tissue reactions, 1984, Volume: 6, Issue:6

    Topics: Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lomustine; Lymphocytes; Male; Mel

1984
Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
    Cancer treatment reports, 1984, Volume: 68, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lomu

1984
A critical review of immunotherapy of disseminated renal adenocarcinoma.
    Journal of surgical oncology, 1982, Volume: 21, Issue:1

    Topics: Adenocarcinoma; BCG Vaccine; Drug Evaluation; Drug Therapy, Combination; Humans; Kidney Neoplasms; L

1982
Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
    Cancer treatment reports, 1980, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lomustine;

1980
Medical treatment of metastatic renal cell carcinoma.
    Tumori, 1980, Apr-30, Volume: 66, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hormones; Humans; Kidney Neop

1980
The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-CD8 Ratio; Dacarbazine;

1996
Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay--can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma?
    Melanoma research, 1996, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined

1996
The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
    The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:12

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C

1998
Bleomycin in testicular teratomas.
    Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 1975, Nov-25, Volume: 84, Issue:3

    Topics: Adult; Bleomycin; Choriocarcinoma; Drug Therapy, Combination; Follow-Up Studies; Humans; Lomustine;

1975
Nonhormonal chemotherapy for disseminated renal cell carcinoma.
    Urology, 1976, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Female; Humans; Kidney Neoplasms; Lomustine;

1976
Combined therapy with bleomycin against malignant melanomas and testicular tumors.
    Progress in biochemical pharmacology, 1976, Volume: 11

    Topics: Abdominal Neoplasms; alpha-Fetoproteins; Bleomycin; Carcinoembryonic Antigen; Drug Administration Sc

1976
Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:9

    Topics: Adolescent; Adult; Aged; Bleomycin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lomu

1976
Hypercalcemia in small cell (oat cell) carcinoma of the lung. Coincident parathyroid adenoma in one case.
    Cancer, 1975, Volume: 36, Issue:3

    Topics: Adenoma; Adult; Bone Neoplasms; Calcitonin; Carcinoma, Small Cell; Cyclophosphamide; Furosemide; Hum

1975
Prevention of brain extension in small-cell carcinoma of the bronchus.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Small Cell; Drug Therapy, Co

1978
Large cell bronchogenic carcinoma. Prolonged disease-free survival following chemotherapy.
    JAMA, 1979, Feb-09, Volume: 241, Issue:6

    Topics: Carcinoma, Bronchogenic; Carcinoma, Small Cell; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged

1979
Schedule dependent effectiveness of CCNU and 5-fluorouracil in experimental chemotherapy.
    European journal of cancer, 1977, Volume: 13, Issue:10

    Topics: Animals; Cell Survival; Drug Therapy, Combination; Fluorouracil; Hematopoietic Stem Cells; Lomustine

1977
Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole.
    Cancer, 1977, Volume: 40, Issue:5 Suppl

    Topics: BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamisole; Lomusti

1977
[Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract].
    Onkologie, 1978, Volume: 1, Issue:5

    Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Hum

1978
Chemotherapy of experimental metastatic brain tumors in female Wistar rats.
    Cancer research, 1979, Volume: 39, Issue:7 Pt 1

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma 256, Walker; Carotid Arteries; Cells, Cul

1979
Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer.
    Cancer, 1978, Volume: 41, Issue:4

    Topics: Adult; Aged; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination;

1978
Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: BCG Vaccine; Blood Cell Count; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Lomust

1976
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
    Minnesota medicine, 1977, Volume: 60, Issue:8

    Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu

1977
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combinatio

1977
Meningeal carcinomatosis. Case report and review of the literature.
    Neurology, 1976, Volume: 26, Issue:3

    Topics: Adult; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lomustine; Meninges; Methotrexa

1976
[Chemotherapy in primary and metastatic intrathoracic cancer].
    Annales de medecine interne, 1976, Volume: 127, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Doxorubicin; Drug Th

1976
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
    Cancer, 1976, Volume: 38, Issue:5

    Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glioma

1976
Growth rate of pulmonary metastases in human sarcomas.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Female; Fibrosarcoma; Hemangiopericytoma; Humans; Le

1975
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.
    Cancer, 1975, Volume: 35, Issue:5

    Topics: Brain Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lomustine; Neoplasm

1975
CCNU in brain tumours.
    Clinical radiology, 1975, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Brain Neoplasms; Bronchial Neoplasms; Cerebellar Neoplasms; Child, Preschool; Fem

1975
Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors.
    European journal of cancer, 1975, Volume: 11, Issue:8

    Topics: Brain Neoplasms; Drug Therapy, Combination; Humans; Lomustine; Methotrexate; Neoplasm Metastasis; Ni

1975
Editorial: Large-bowel cancer-The current status of treatment.
    Journal of the National Cancer Institute, 1976, Volume: 56, Issue:1

    Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi

1976
Editorial: Large-bowel cancer-The current status of treatment.
    Journal of the National Cancer Institute, 1976, Volume: 56, Issue:1

    Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi

1976
Editorial: Large-bowel cancer-The current status of treatment.
    Journal of the National Cancer Institute, 1976, Volume: 56, Issue:1

    Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi

1976
Editorial: Large-bowel cancer-The current status of treatment.
    Journal of the National Cancer Institute, 1976, Volume: 56, Issue:1

    Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi

1976
Phase II study of methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Drug Evaluation; Female; Gastrointestinal Neo

1976
Combined chemotherapy (cisplatin, cyclophosphamide, lomustine and vincristine) and multifractionation radiotherapy in inoperable nonmetastatic squamous cell lung cancer.
    Neoplasma, 1992, Volume: 39, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

1992
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
    British journal of cancer, 1990, Volume: 61, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo

1990
Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma.
    Cancer treatment reports, 1986, Volume: 70, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation;

1986
Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
    Cancer, 1988, Jun-01, Volume: 61, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Humans; Lomustine; Melanoma;

1988
Palliative and adjuvant chemotherapy of metastatic renal cancer.
    Seminars in surgical oncology, 1988, Volume: 4, Issue:2

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Hu

1988
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
    Cancer, 1985, May-01, Volume: 55, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administra

1985
Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; L

1985
A 10-year experience with combined modality therapy for stage III small cell lung carcinoma.
    Cancer, 1986, Nov-15, Volume: 58, Issue:10

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modalit

1986
Prognostic factors in patients with small-cell carcinoma of the lung.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1986, Dec-20, Volume: 70, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide

1986
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
    American journal of clinical oncology, 1986, Volume: 9, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Lomust

1986
[Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma].
    No shinkei geka. Neurological surgery, 1985, Volume: 13, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Cerebellar Neoplasms; C

1985